Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
One Percent Rule Checklist For Safer Forex Trading Risk 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
NEW YORK, April 24, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of BioAmber Inc. (“BioAmber”) (NYSE:BIOA) (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017; and/or (2) on the open market from January 23, 2017 through March 16, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra/bioamber-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period BioAmber made materially false and/or misleading statements and/or failed to disclose that: (1) a large customer of BioAmber that was expected to purchase $2.8 million of succinic acid in Q4 2016 experienced a technical problem in its manufacturing facility and postponed the order to 2017; and (2) as a result, defendants’ statements about BioAmber’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in BioAmber you have until May 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
